Voyager Therapeutics, Inc.
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Nov 10, 2026 (14 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Nov 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $25 | 44% |
| Sep 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Aug 7, 2025 | Wedbush | maintain | Outperform → Outperform | $8 | 58% |
| Apr 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Mar 13, 2025 | Canaccord Genuity | maintain | Buy → Buy | $12 | 48% |
| Mar 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Mar 12, 2025 | Wells Fargo | maintain | Overweight → Overweight | $10 | 54% |
| Mar 12, 2025 | Wedbush | reiterate | Outperform → Outperform | $0 | 58% |
| Mar 12, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 10, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $5.73 | 50% |
| Dec 2, 2024 | Citigroup | initiate | — → Buy | $12 | 54% |
| Nov 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| Nov 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Oct 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Oct 16, 2024 | Leerink Partners | initiate | — → Outperform | $15 | 51% |
| Aug 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Aug 7, 2024 | Wedbush | maintain | Neutral → Neutral | $7 | 58% |
| Jul 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| May 15, 2024 | Oppenheimer | maintain | Outperform → Outperform | $18 | 52% |
| May 14, 2024 | Wedbush | maintain | Neutral → Neutral | $8 | 58% |
| Mar 26, 2024 | Guggenheim | initiate | — → Buy | $22 | 52% |
| Mar 19, 2024 | HC Wainwright & Co. | initiate | — → Buy | $30 | 44% |
| Mar 7, 2024 | Citigroup | initiate | — → Buy | $16 | 54% |
| Jan 2, 2024 | Wells Fargo | upgrade | Equal-Weight → Overweight | $14 | 54% |
| Aug 7, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $16 | 52% |
| May 10, 2023 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| May 10, 2023 | Truist Securities | initiate | — → Buy | $18 | 55% |
| Mar 10, 2023 | Oppenheimer | initiate | — → Outperform | $14 | 52% |
| Nov 3, 2021 | Chardan Capital | maintain | — → Neutral | $4 | 47% |
| Oct 7, 2021 | Baird | upgrade | Neutral → Outperform | $9 | 55% |
| Apr 19, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $6 | 54% |
| Feb 26, 2021 | Baird | downgrade | Outperform → Neutral | $6 | 55% |
| Feb 3, 2021 | Wedbush | downgrade | Outperform → Neutral | $6 | 58% |
| Feb 3, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $7 | 54% |
| Feb 3, 2021 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Nov 11, 2020 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Nov 10, 2020 | Raymond James | downgrade | Strong Buy → Outperform | $17 | 54% |
| Nov 10, 2020 | Wells Fargo | downgrade | Overweight → Equal-Weight | $10 | 54% |
| Aug 4, 2020 | HC Wainwright & Co. | maintain | — → Buy | $14 | 44% |
| Apr 15, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $13 | 54% |
| Mar 30, 2020 | Nomura | maintain | — → Buy | $16 | — |
| Mar 19, 2020 | Benchmark | initiate | — → Buy | $18 | 54% |
| Mar 4, 2020 | HC Wainwright & Co. | maintain | — → Buy | $18 | 44% |
| Mar 4, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $14 | 54% |
| Mar 4, 2020 | Wedbush | maintain | — → Outperform | $27 | 58% |
No cross-platform signals in the last 90 days